1660159-36-3
Chemical Structure
Inotuzumab
Synonym(s): Humanized Anti-CD22 Recombinant Antibody
- CAS No.: 1660159-36-3
- Formula:N/A
- Molecular Weight:(146.48 kDa)
IUPAC Name: (S)-3-acetamido-4-(((S)-1-(((S)-1-((S)-2-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-4-(methylthio)-1-oxobutan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)amino)-1-oxo-3-(4-(phosphonooxy)phenyl)propan-2-yl)amino)-4-oxobutanoic acid
SMILES: [Inotuzumab]
Biological Activity: Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Inotuzumab | 97.66% | Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inotuzumab (powder) | Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9. [Content Brief]
- [2]. Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3(1):96-104. [Content Brief]
- [3]. Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137(19):2657-2661. [Content Brief]
- [4]. Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18(5):1101-1116. [Content Brief]
